147 related articles for article (PubMed ID: 38393945)
21. Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.
Yanaihara N; Hirata Y; Yamaguchi N; Noguchi Y; Saito M; Nagata C; Takakura S; Yamada K; Okamoto A
Mol Carcinog; 2016 May; 55(5):832-41. PubMed ID: 25856562
[TBL] [Abstract][Full Text] [Related]
22. The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling.
Baran P; Hansen S; Waetzig GH; Akbarzadeh M; Lamertz L; Huber HJ; Ahmadian MR; Moll JM; Scheller J
J Biol Chem; 2018 May; 293(18):6762-6775. PubMed ID: 29559558
[TBL] [Abstract][Full Text] [Related]
23. The Soluble Interleukin 6 Receptor: Advanced Therapeutic Options in Inflammation.
Rose-John S
Clin Pharmacol Ther; 2017 Oct; 102(4):591-598. PubMed ID: 28675418
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic blockade of the interleukin-6 receptor (IL-6R) allows sIL-6R generation by proteolytic cleavage.
Prenissl N; Lokau J; Rose-John S; Haybaeck J; Garbers C
Cytokine; 2019 Feb; 114():1-5. PubMed ID: 30557809
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor.
Garbers C; Thaiss W; Jones GW; Waetzig GH; Lorenzen I; Guilhot F; Lissilaa R; Ferlin WG; Grötzinger J; Jones SA; Rose-John S; Scheller J
J Biol Chem; 2011 Dec; 286(50):42959-70. PubMed ID: 21990364
[TBL] [Abstract][Full Text] [Related]
26. IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19.
Kishimoto T; Kang S
Annu Rev Immunol; 2022 Apr; 40():323-348. PubMed ID: 35113729
[TBL] [Abstract][Full Text] [Related]
27. Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling.
Hashizume M; Mihara M
Rheumatol Int; 2009 Feb; 29(4):397-401. PubMed ID: 18802703
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-6 controls recycling and degradation, but not internalization of its receptors.
Flynn CM; Kespohl B; Daunke T; Garbers Y; Düsterhöft S; Rose-John S; Haybaeck J; Lokau J; Aparicio-Siegmund S; Garbers C
J Biol Chem; 2021; 296():100434. PubMed ID: 33610555
[TBL] [Abstract][Full Text] [Related]
29. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.
Kang S; Tanaka T; Inoue H; Ono C; Hashimoto S; Kioi Y; Matsumoto H; Matsuura H; Matsubara T; Shimizu K; Ogura H; Matsuura Y; Kishimoto T
Proc Natl Acad Sci U S A; 2020 Sep; 117(36):22351-22356. PubMed ID: 32826331
[TBL] [Abstract][Full Text] [Related]
30. IL-6/IL-6 receptor system and its role in physiological and pathological conditions.
Mihara M; Hashizume M; Yoshida H; Suzuki M; Shiina M
Clin Sci (Lond); 2012 Feb; 122(4):143-59. PubMed ID: 22029668
[TBL] [Abstract][Full Text] [Related]
31. Editorial: Tocilizumab, a Humanized Therapeutic IL-6 Receptor (IL-6R) Monoclonal Antibody, and Future Combination Therapies for Severe COVID-19.
Parums DV
Med Sci Monit; 2021 Jul; 27():e933973. PubMed ID: 34276042
[TBL] [Abstract][Full Text] [Related]
32. Minimal interleukin 6 (IL-6) receptor stalk composition for IL-6 receptor shedding and IL-6 classic signaling.
Baran P; Nitz R; Grötzinger J; Scheller J; Garbers C
J Biol Chem; 2013 May; 288(21):14756-68. PubMed ID: 23564454
[TBL] [Abstract][Full Text] [Related]
33. Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis.
Lee EB; Daskalakis N; Xu C; Paccaly A; Miller B; Fleischmann R; Bodrug I; Kivitz A
Clin Pharmacokinet; 2017 Jun; 56(6):607-615. PubMed ID: 27722854
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-6 as a key player in systemic inflammation and joint destruction.
Fonseca JE; Santos MJ; Canhão H; Choy E
Autoimmun Rev; 2009 Jun; 8(7):538-42. PubMed ID: 19189867
[TBL] [Abstract][Full Text] [Related]
35. [Humanized anti-human IL-6 receptor antibody, tocilizumab].
Nishimoto N
Nihon Rinsho; 2007 Jul; 65(7):1218-25. PubMed ID: 17642235
[TBL] [Abstract][Full Text] [Related]
36. A Hybrid Soluble gp130/Spike-Nanobody Fusion Protein Simultaneously Blocks Interleukin-6
Ettich J; Werner J; Weitz HT; Mueller E; Schwarzer R; Lang PA; Scheller J; Moll JM
J Virol; 2022 Feb; 96(4):e0162221. PubMed ID: 34935434
[TBL] [Abstract][Full Text] [Related]
37. Unraveling viral interleukin-6 binding to gp130 and activation of STAT-signaling pathways independently of the interleukin-6 receptor.
Adam N; Rabe B; Suthaus J; Grötzinger J; Rose-John S; Scheller J
J Virol; 2009 May; 83(10):5117-26. PubMed ID: 19264784
[TBL] [Abstract][Full Text] [Related]
38. The Importance of the Timing of Tocilizumab Administration in Moderate to Severely Ill COVID-19: Single Centered Experience Case series.
Tenda ED; Andrian S; Albert S; Asaf MM; Pitoyo CW; Setiati S; Subekti I
Acta Med Indones; 2021 Jul; 53(3):319-325. PubMed ID: 34611072
[TBL] [Abstract][Full Text] [Related]
39. What do we know about IL-6 in COVID-19 so far?
Jiang J; Wang J; Yao L; Lai S; Zhang X
Biophys Rep; 2021 Jun; 7(3):193-206. PubMed ID: 37287491
[TBL] [Abstract][Full Text] [Related]
40. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6.
Rose-John S
Int J Biol Sci; 2012; 8(9):1237-47. PubMed ID: 23136552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
